JP2025503385A - メニン－ｍｌｌエピジェネティック複合体を破壊することによる消化管間質腫瘍（ｇｉｓｔ）の治療的標的化 - Google Patents

メニン－ｍｌｌエピジェネティック複合体を破壊することによる消化管間質腫瘍（ｇｉｓｔ）の治療的標的化 Download PDF

Info

Publication number
JP2025503385A
JP2025503385A JP2024533005A JP2024533005A JP2025503385A JP 2025503385 A JP2025503385 A JP 2025503385A JP 2024533005 A JP2024533005 A JP 2024533005A JP 2024533005 A JP2024533005 A JP 2024533005A JP 2025503385 A JP2025503385 A JP 2025503385A
Authority
JP
Japan
Prior art keywords
inhibitor
menin
moz
gist
tki
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503385A5 (cg-RX-API-DMAC10.html
Inventor
スコット エー． アームストロング，
マシュー エル． ヘミング，
Original Assignee
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド filed Critical ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Publication of JP2025503385A publication Critical patent/JP2025503385A/ja
Publication of JP2025503385A5 publication Critical patent/JP2025503385A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024533005A 2021-12-15 2022-12-14 メニン－ｍｌｌエピジェネティック複合体を破壊することによる消化管間質腫瘍（ｇｉｓｔ）の治療的標的化 Pending JP2025503385A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163289943P 2021-12-15 2021-12-15
US63/289,943 2021-12-15
PCT/US2022/081587 WO2023114867A2 (en) 2021-12-15 2022-12-14 Therapeutic targeting of gastrointestinal stromal tumor (gist) by disrupting the menin-mll epigenetic complex

Publications (2)

Publication Number Publication Date
JP2025503385A true JP2025503385A (ja) 2025-02-04
JP2025503385A5 JP2025503385A5 (cg-RX-API-DMAC10.html) 2025-12-22

Family

ID=86773651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533005A Pending JP2025503385A (ja) 2021-12-15 2022-12-14 メニン－ｍｌｌエピジェネティック複合体を破壊することによる消化管間質腫瘍（ｇｉｓｔ）の治療的標的化

Country Status (10)

Country Link
US (1) US20250041299A1 (cg-RX-API-DMAC10.html)
EP (1) EP4447972A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025503385A (cg-RX-API-DMAC10.html)
KR (1) KR20240121720A (cg-RX-API-DMAC10.html)
CN (1) CN118234497A (cg-RX-API-DMAC10.html)
AU (1) AU2022410890A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235383A1 (cg-RX-API-DMAC10.html)
IL (1) IL311862A (cg-RX-API-DMAC10.html)
MX (1) MX2024007201A (cg-RX-API-DMAC10.html)
WO (1) WO2023114867A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
US12187732B2 (en) 2022-03-28 2025-01-07 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
AR132185A1 (es) 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
JP2026525148A (ja) * 2023-07-17 2026-07-29 クラ オンコロジー，インク． メニン阻害剤を含む医薬組成物
IL325861A (en) 2023-07-17 2026-03-01 Kura Oncology Inc Crystalline forms of a menin inhibitor
KR20260099138A (ko) * 2023-10-20 2026-06-26 얀센 파마슈티카 엔브이 암 치료에 사용하기 위한, (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드, 이의 제제 및 이의 투여 요법
IL328224A (en) * 2023-11-17 2026-07-01 Kura Oncology Inc Methods for treating KIT-positive cancer with a menin inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197027A1 (en) * 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
US10752639B2 (en) * 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
WO2017161028A1 (en) * 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
JP2022503792A (ja) * 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置

Also Published As

Publication number Publication date
IL311862A (en) 2024-06-01
WO2023114867A2 (en) 2023-06-22
KR20240121720A (ko) 2024-08-09
CN118234497A (zh) 2024-06-21
US20250041299A1 (en) 2025-02-06
EP4447972A2 (en) 2024-10-23
EP4447972A4 (en) 2025-12-31
WO2023114867A3 (en) 2023-07-27
MX2024007201A (es) 2024-08-06
CA3235383A1 (en) 2023-06-22
AU2022410890A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
US20250041299A1 (en) Therapeutic targeting of gastrointestinal stromal tumor (gist) by disrupting the menin-mll epigenetic complex
US20240118266A1 (en) Cell death biomarker
WO2015160986A2 (en) Combination therapies
US12516024B2 (en) KDM4 inhibitors
US12290521B2 (en) Methods and materials for identifying and treating BET inhibitor-resistant cancers
Timme et al. Small-molecule dual PLK1 and BRD4 inhibitors are active against preclinical models of pediatric solid tumors
Martínez-Martín et al. MYC inhibitors in multiple myeloma
US20230158034A1 (en) Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
US20220288067A1 (en) Treatment of cancer with cdk inhibitors
Bertrand et al. PCDH10 is a candidate tumour suppressor gene in medulloblastoma
Li et al. NUP98‐p65 complex regulates DNA repair to maintain glioblastoma stem cells
WO2021176008A1 (en) Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
US20250146080A1 (en) Methods for overcoming tazemetostat-resistance in cancer patients
EP3664807A2 (en) Methods and materials for identifying and treating bet inhibitor-resistant cancers
EP3900789A1 (en) Pharmaceutical combination for the treatment of myeloproliferative neoplasms
US10213449B2 (en) Compositions and methods for treating medulloblastoma
US20240398814A1 (en) Kras inhibitor and hdac inhibitor combination for the treatment of cancer
Walton et al. PRMT1 is a critical dependency in clear cell renal cell carcinoma through its role in post-transcriptional regulation of DNA damage response genes
US20240350488A1 (en) Methods of treating swi/snf deregulated cancers
Gois et al. S6K1 and S6K2 regulate homologous recombination DNA repair through control of BRCA1 protein stability
Cullinane et al. Targeting the ribosome to treat multiple myeloma
Agosto-Peña Role of ASXL1 Mutations in Leukemogenesis and Genomic Integrity
Oldberg Elucidating the Novel Role for Core Binding Factor beta in Osteosarcoma Protein Translation
Fantozzi Influence of centrosome amplification on the response to chemotherapy in epithelial ovarian cancer
WO2025054356A1 (en) Bet inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251212